Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Drop in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 15,700 shares, a decrease of 29.0% from the February 13th total of 22,100 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Basilea Pharmaceutica Price Performance

BPMUF stock opened at $52.83 on Friday. Basilea Pharmaceutica has a twelve month low of $38.60 and a twelve month high of $52.83. The business has a 50 day simple moving average of $52.83 and a 200-day simple moving average of $52.48. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.10 and a quick ratio of 3.27.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Read More

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.